Clinical Trial

Shortened LSD Intervention for Major Depressive Disorder

Study acronym: SLIM
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-03-25; most recent amendment 2026-07-23.
Trial Details
NCT Number NCT07503002
Lead Sponsor Johns Hopkins University
Conditions Major Depression Moderate, Major Depression Severe, Major Depression
Enrollment 10 participants
Start Date 2026-08-31
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-24